[Antitumor activity and pharmacological properties of furizil].
The paper discusses the biological properties of 2-(2-furyl)-5-oxymethyl-5-(2,4-diethyleneimino-1,3,5-triazine- 6-yl) amino-1,3-dioxane (furizil), synthesized by substituting ethyleneimine groups for chlorine atoms in individual stereoisomer of a dichlorotriazine derivative. Furizil was found to inhibit the growth of Ehrlich's tumor, Walker's carcinosarcoma, sarcoma 45 and rat ovarian tumors, the inhibition rate ranging 76-100%. Parenterally administered, LD50 appeared to be 6 mg/kg for rats and 15 mg/kg for mice. Studies of chronic toxicity established damaging effects of furizil on hematopoietic, gastrointestinal and reproductive organs. Toxic effects subsided 1-2 weeks after the drug withdrawal.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001388:Aziridines / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001389:Azirines / Q000627:therapeutic use*; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D006168:Guinea Pigs; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011817:Rabbits; D051381:Rats; D014227:Triazines / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity
D000970:Antineoplastic Agents; D001388:Aziridines; D001389:Azirines; D014227:Triazines; C045868:furisyl
Protivoopukholevaia aktivnost' i farmakologicheskie svoĭstva furizila.